SpringWorks Therapeutics, Inc. clinical trials
Acquired by Merck KGaA, Darmstadt, Germany, Jul 1, 2025 · source ↗
The registry lists 14 studies whose lead sponsor is SpringWorks Therapeutics, Inc.. 6 are recruiting or about to start. Per ClinicalTrials.gov, last updated Oct 21, 2026.
Before and after it joined Merck KGaA, Darmstadt, Germany
- First submitted before SpringWorks Therapeutics, Inc. became part of Merck KGaA, Darmstadt, Germany
- 8
- First submitted after SpringWorks Therapeutics, Inc. became part of Merck KGaA, Darmstadt, Germany
- 6
- Unclear, or no submission date
- 0
By the date each study was first submitted to the registry. The registry lists today's sponsor name and keeps no history, so this says when a study was filed, not who filed it.
Registry sponsor names on this page
- SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany14 studies
Something wrong with this grouping? Tell us on the Merck KGaA, Darmstadt, Germany page.
Studies
Recruiting first, then most recently updated. Showing 14 of 14. All Merck KGaA, Darmstadt, Germany studies →
- A Study of Mirdametinib in Infants and Toddlers With Neurofibromatosis Type 1 Associated Plexiform NeurofibromasNot yet recruitingNCT07850635Phase 1
Sponsor listed in the registry: SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany · First submitted after SpringWorks Therapeutics, Inc. became part of Merck KGaA, Darmstadt, Germany
- Effect of Hepatic Impairment on the Pharmacokinetics of MirdametinibRecruitingNCT06997276Phase 1
Sponsor listed in the registry: SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany · First submitted before SpringWorks Therapeutics, Inc. became part of Merck KGaA, Darmstadt, Germany
- Nirogacestat in Premenopausal Females With Desmoid Tumor/Aggressive Fibromatosis (DT/AF)RecruitingNCT07176689Phase 4
Sponsor listed in the registry: SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany · First submitted after SpringWorks Therapeutics, Inc. became part of Merck KGaA, Darmstadt, Germany
- Individual Patient Compassionate Use of MirdametinibAvailableNCT05028166
Sponsor listed in the registry: SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany · First submitted before SpringWorks Therapeutics, Inc. became part of Merck KGaA, Darmstadt, Germany
- Individual Patient Compassionate Use of NirogacestatAvailableNCT05041036
Sponsor listed in the registry: SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany · First submitted before SpringWorks Therapeutics, Inc. became part of Merck KGaA, Darmstadt, Germany
- SW-682 in Advanced Solid TumorsRecruitingNCT06251310Phase 1
Sponsor listed in the registry: SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany · First submitted before SpringWorks Therapeutics, Inc. became part of Merck KGaA, Darmstadt, Germany
- MEK Inhibitor Mirdametinib (PD-0325901) in Patients With Neurofibromatosis Type 1 Associated Plexiform NeurofibromasActive, not recruitingNCT03962543Phase 2
Sponsor listed in the registry: SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany · First submitted before SpringWorks Therapeutics, Inc. became part of Merck KGaA, Darmstadt, Germany
- A Study of Nirogacestat in Japanese Adults With Desmoid Tumors/Aggressive Fibromatosis (DT/AF)Active, not recruitingNCT07170644Phase 2
Sponsor listed in the registry: SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany · First submitted after SpringWorks Therapeutics, Inc. became part of Merck KGaA, Darmstadt, Germany
- Nirogacestat in Ovarian Granulosa Cell TumorsCompletedNCT05348356Phase 2
Sponsor listed in the registry: SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany · First submitted before SpringWorks Therapeutics, Inc. became part of Merck KGaA, Darmstadt, Germany
- Mirdametinib + BGB-3245 in Advanced Solid TumorsTerminatedNCT05580770Phase 1/2
Sponsor listed in the registry: SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany · First submitted before SpringWorks Therapeutics, Inc. became part of Merck KGaA, Darmstadt, Germany
- Nirogacestat for Adults With Desmoid Tumor/Aggressive Fibromatosis (DT/AF)CompletedNCT03785964Phase 3
Sponsor listed in the registry: SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany · First submitted before SpringWorks Therapeutics, Inc. became part of Merck KGaA, Darmstadt, Germany
- To Assess the Enzyme Inducing Effects of Carbamazepine on the PK of Mirdametinib in Healthy ParticipantsCompletedNCT07279233Phase 1
Sponsor listed in the registry: SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany · First submitted after SpringWorks Therapeutics, Inc. became part of Merck KGaA, Darmstadt, Germany
- Evaluate the Effects of Famotidine or Rabeprazole on the PK of NirogacestatCompletedNCT07171619Phase 1
Sponsor listed in the registry: SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany · First submitted after SpringWorks Therapeutics, Inc. became part of Merck KGaA, Darmstadt, Germany
- To Determine the Effect of CYP Induction Following Administration of Nirogacestat in Healthy Adult Male ParticipantsCompletedNCT07259330Phase 1
Sponsor listed in the registry: SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany · First submitted after SpringWorks Therapeutics, Inc. became part of Merck KGaA, Darmstadt, Germany